.Nature Medicine, Published online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint asks for addition of people with MASLD and measurement of liver end results in cardio-- kidney-- metabolic trials, when data suggest mechanistically probable perks and professional security-- and also outlines factors to consider for test concept and regulatory approval.